PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Patient and Physician Voice of the Customer for U.S. Drug Delivery - Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market
New Patient and Physician Voice of the Customer for U.S. Drug Delivery

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/07/21 - Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Following successful work in the areas of diabetes, chronic pain, inflammation and neurological disorders, Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.

Through interviews with both physicians and patients, Frost & Sullivan aims to identify key drivers and obstacles to adoption and utilization of various drug delivery technologies. Additionally, patient feedback will be obtained in terms of awareness, usage, and desired improvements of specific brands as determined by clients.

Frost & Sullivan seeks feedback on areas of interest to the industry for an in-depth look at these issues from respondents. Various new therapeutic areas and treatment settings are being evaluated. The final decision for this new project will be based on market demand and shaped to meet the needs of the industry.

If you are interested in partnering with us, shaping, or obtaining the research for the study U.S. Drug Delivery Voice of the Customer 2008, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state and country.

“Understanding how patients and prescribers view drug delivery methods as part of treatment is vital to drug developers throughout the industry,” notes Frost & Sullivan Industry Manager Daniel Ruppar. “Especially as companies evaluate new delivery opportunities, understanding how different technologies are viewed may lead to new product pathways not previously considered.”

While there are numerous types of drug delivery technologies available in terms of approved drugs for a disease, physician and patient decision factors are often the primary determinant of drug choice. This can especially impact drugs using device-driven drug delivery, or the success of new first-in-class products with novel delivery approaches.

“Developers that can better understand the drivers and obstacles of adoption and utilization preferences for pharmaceutical drug delivery can develop and refine their technologies to best serve patients and the medical community,” says Ruppar. “This can also drive decision factors for both lifecycle management activities and R&D programs.”

U.S. Drug Delivery Voice of the Customer 2008 is part of ongoing research conducted within the Pharmaceutical and Biotechnology Subscription, which also includes research in the following markets: Contract Research & Manufacturing, Biopharmaceuticals, Specialty Pharmaceuticals, Vaccines and Drug Delivery. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Patient and Physician Voice of the Customer for U.S. Drug Delivery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)